Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 12;44(38):3911-3925.
doi: 10.1093/eurheartj/ehad334.

Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome

Teresa Gerhardt  1   2   3 , Claudio Seppelt  1   2   4   5 , Youssef S Abdelwahed  1   2 , Denitsa Meteva  1   2 , Christopher Wolfram  1 , Philip Stapmanns  1 , Aslihan Erbay  1   2   4   5 , Lukas Zanders  1   2 , Gregor Nelles  4   5 , Johanna Musfeld  1 , Lara Sieronski  1   2 , Barbara E Stähli  6 , Rocco A Montone  7 , Rocco Vergallo  7 , Arash Haghikia  1   2 , Carsten Skurk  1   2 , Fabian Knebel  2   8   9 , Henryk Dreger  2   8 , Tobias D Trippel  2   10 , Himanshu Rai  11   12   13 , Michael Joner  11   14 , Jens Klotsche  15 , Peter Libby  16   17 , Filippo Crea  7   18 , Nicolle Kränkel  1   2 , Ulf Landmesser  1   2 , David M Leistner  1   2   4   5 ; OPTICO-ACS study group
Affiliations

Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome

Teresa Gerhardt et al. Eur Heart J. .

Abstract

Aims: Rupture of the fibrous cap (RFC) and erosion of an intact fibrous cap (IFC) are the two predominant mechanisms causing acute coronary syndromes (ACS). It is uncertain whether clinical outcomes are different following RFC-ACS vs. IFC-ACS and whether this is affected by a specific inflammatory response. The prospective, translational OPTIcal-COherence Tomography in Acute Coronary Syndrome study programme investigates the impact of the culprit lesion phenotype on inflammatory profiles and prognosis in ACS patients.

Methods and results: This analysis included 398 consecutive ACS patients, of which 62% had RFC-ACS and 25% had IFC-ACS. The primary endpoint was a composite of cardiac death, recurrent ACS, hospitalization for unstable angina, and target vessel revascularization at 2 years [major adverse cardiovascular events (MACE+)]. Inflammatory profiling was performed at baseline and after 90 days. Patients with IFC-ACS had lower rates of MACE+ than those with RFC-ACS (14.3% vs. 26.7%, P = 0.02). In 368-plex proteomic analyses, patients with IFC-ACS showed lower inflammatory proteome expression compared with those with RFC-ACS, including interleukin-6 and proteins associated with the response to interleukin-1β. Circulating plasma levels of interleukin-1β decreased from baseline to 3 months following IFC-ACS (P < 0.001) but remained stable following RFC-ACS (P = 0.25). Interleukin-6 levels decreased in patients with RFC-ACS free of MACE+ (P = 0.01) but persisted high in those with MACE+.

Conclusion: This study demonstrates a distinct inflammatory response and a lower risk of MACE+ following IFC-ACS. These findings advance our understanding of inflammatory cascades associated with different mechanisms of plaque disruption and provide hypothesis generating data for personalized anti-inflammatory therapeutic allocation to ACS patients, a strategy that merits evaluation in future clinical trials.

Keywords: Clinical outcome; IFC-ACS; Interleukin-6; Plaque erosion; RFC-ACS; Residual inflammatory risk.

PubMed Disclaimer

Comment in

LinkOut - more resources